ライフサイエンスコーパス: TACE

1 TACE achieved a promising outcome in select patients wit

2 TACE activation is central to the pathogenesis of NASH a

3 TACE activation requires the mitogen-activated protein k

4 TACE and AREG, but not TGF-alpha, were overexpressed in

5 TACE deficiency in oligodendrocyte progenitor cells foll

6 TACE genetic depletion in OPs abrogates EGFR activation

7 TACE is a major shedding protease, responsible for the l

8 TACE is a potential target to treat TNF-alpha-dependent

9 TACE is an effective treatment for inoperable hepatic tu

10 TACE plus RT was more therapeutically beneficial than TA

11 TACE with drug-eluting beads (DEB-TACE), a novel drug de

12 There were 41 (RS, 11; TACE MWA, 30) instances of progression occurring after a

13 , median age 63 (34-84) years] underwent 111 TACE sessions.

14 42 (38.2%) TACE procedures resulted in complications [PEF 28 (25.2%

15 ly undergone local-regional therapy (RS, 41; TACE MWA, 80; mean age, 65.4 years; 84 men [69.4%]) and

16 c mice, albuminuria, increased Src pTyr-416, TACE activation, ERK and EGFR phosphorylation, glomerula

17 een developed to reduce the variability in a TACE procedure.

18 JCI, Issuree et al. report that iRHOM2 is a TACE activator in immune cells.

19 tegrin receptors by magnetic beads activated TACE and shed HB-EGF and TGF-alpha.

20 cal strain of fetal epithelial cells actives TACE, releases HB-EGF and TGF-alpha, and promotes differ

21 decreased TACE promoter luciferase activity, TACE expression, and TACE enzymatic activity in wtDCs or

22 increased TACE promoter luciferase activity, TACE expression, and TACE enzymatic activity in wtDCs.

23 vents premature Neogenin shedding by ADAM17 (TACE).

24 substrate ectodomain sheddase enzyme ADAM17 (TACE) in macrophages.

25 o paralleled the reduced activity of ADAM17 (TACE).

26 ment of metalloproteinases ADAM10 and ADAM17/TACE that are responsible for sCD30 shedding were also a

27 id not alter the levels of ADAM10 and ADAM17/TACE.

28 nd TGF-alpha is mediated via integrin-ADAM17/TACE interactions.

29 ferentiation via alpha6beta1 integrin-ADAM17/TACE signaling pathway.

30 Redox modulation also affected TACE activation, diminishing LAG-3 cleavage.

31 After TACE with 70-150-mum SEBs, ITSC was 40.4 mug/g on day 1

32 n of VEGFR2 was inhibited until day 14 after TACE with both sizes of SEBs.

33 to compare images obtained before and after TACE showed a significant reduction in tumor enhancement

34 cone-beam CT was performed before and after TACE.

35 ween tumor enhancement at cone-beam CT after TACE and complete and/or partial tumor response at MR im

36 ment seen with dual-phase cone-beam CT after TACE showed a linear correlation with MR findings.

37 e cone-beam CT can be used immediately after TACE with doxorubicin-eluting beads to predict HCC tumor

38 The ADC ratio 1 month after TACE was an independent predictor of PFS, which showed s

39 Responses 1 month after TACE were assessed with the ADC change relative to basel

40 cluding DW imaging, before and 1 month after TACE.

41 was performed at baseline and 1 month after TACE.

42 nts underwent transplantation 4 months after TACE, allowing the association between response and hist

43 Results Maximum PSC after TACE with 100-300-mum SEBs was 0.002 mug/mL on day 1.

44 ing was performed before and 3-4 weeks after TACE, and images were analyzed with a semiautomatic volu

45 Although TACE achieves substantial necrosis of the tumor, complet

46 ity against ADAMTS-1, ADAMTS-13, MMP-13, and TACE.

47 and TNFko DCs, indicating that AP-2alpha and TACE are inversely dependent on sTNF and are functionall

48 hHSC time dependently expressed AR and TACE.

49 er luciferase activity, TACE expression, and TACE enzymatic activity in wtDCs or TNFko DCs.

50 er luciferase activity, TACE expression, and TACE enzymatic activity in wtDCs.

51 ng that MUC1 is required for CSE-induced and TACE-mediated TNF-alpha secretion.

52 llate cells by a NOX2-dependent pathway, and TACE was induced after exposure to AGEs.

53 ma-secretase cleavage complex (PS1, PS2) and TACE (ADAM17), which releases the Trop2 intracellular do

54 nsecutive patients with HCC underwent RS and TACE MWA, respectively.

55 production of reactive oxidative species and TACE activity significantly increased with an increase i

56 to DCA resulted in colocalization of Src and TACE to the cell membrane, resulting in AREG-dependent a

57 Median overall survival in TEA and TACE was 24.3 months (95% confidence interval [CI]: 12.8

58 d no significant change in Sirt1, Timp3, and TACE activity or the fibrosis markers assessed.

59 The role of NOX2, Sirt1, Timp3, and TACE was evaluated in choline-deficient L-amino acid def

60 noprecipitation experiments in wild-type and TACE knock-out cells using several TACE constructs demon

61 nd metalloprotease 17 (ADAM17; also known as TACE) was found to be critical for hBD-3 induction, whil

62 ity over other zinc metalloproteases such as TACE, MMP2, MMP3, MMP13, and MMP14.

63 TPD significantly attenuated TACE-mediated disease models of sepsis, rheumatoid arthr

64 ncerns about potential side effects, because TACE also protects the skin and intestinal barrier by ac

65 However, because TACE cleaves other proteins involved in development and

66 ion type, presence of PVTT, and time between TACE and RT.

67 iRhom2 binds TACE and promotes its exit from the endoplasmic reticulu

68 atic HCC, treatment of intrahepatic tumor by TACE may be associated with improved survival.

69 Transarterial chemoembolisation (TACE) is the standard of care for patients with intermed

70 to transcatheter arterial chemoembolization (TACE) based on immune markers and tumor biology in patie

71 Transcatheter arterial chemoembolization (TACE) is currently considered a first-line therapy for u

72 Transcatheter arterial chemoembolization (TACE) is the first-line therapy recommended for patients

73 Transcatheter arterial chemoembolization (TACE) is the standard of care for patients with asymptom

74 er transcatheter arterial chemoembolization (TACE) with two different sizes of sunitinib-eluting bead

75 orafenib or transarterial chemoembolization (TACE) by HCC-associated comorbidities.

76 my (RS) and transarterial chemoembolization (TACE) combined with microwave ablation (MWA) in the trea

77 iodol-based transarterial chemoembolization (TACE) has been performed for over 3 decades for the trea

78 ation (TAE)/transarterial chemoembolization (TACE) in a state of cell cycle arrest-a function that ma

79 atment with transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC).

80 mbined with transarterial chemoembolization (TACE) in treating pediatric hepatoblastoma.

81 Transarterial chemoembolization (TACE) is the main treatment for intermediate stage hepat

82 n (RFA) +/- transarterial chemoembolization (TACE) or surgical resection by conducting a systematic r

83 r the first transarterial chemoembolization (TACE) procedure.

84 Transarterial chemoembolization (TACE) using lipiodol-based regimens, including the admin

85 Transarterial chemoembolization (TACE) was similarly applied to the two groups (60% vs. 6

86 reated with transarterial chemoembolization (TACE).

87 neoadjuvant transarterial chemoembolization (TACE).

88 bead (DEB) transarterial chemoembolization (TACE).

89 All patients received chemotherapy, TACE, and HIFU ablation.

90 Constitutive TACE depletion in OPs in vivo leads to similar alteratio

91 Conventional TACE with doxorubicin, cisplatin, and Ethiodol was perfo

92 py for liver cancer with either conventional TACE or TACE with drug-eluting beads.

93 sponse rates trended higher for conventional TACE (conventional TACE, 65.4%; DEBDOX, 63.8%; hqTACE, 5

94 d higher for conventional TACE (conventional TACE, 65.4%; DEBDOX, 63.8%; hqTACE, 53.8%) (P = .085).

95 own to have similar efficacy to conventional TACE (cTACE); it also exhibits fewer adverse effects res

96 Thirty-four patients underwent conventional TACE with doxorubicin plus lipiodol or TACE with drug-el

97 esponse rates when treated with conventional TACE, but no significant differences were seen for DEBDO

98 the maturation of the TNF-alpha convertase (TACE), which controls shedding of TNF-alpha and its biol

99 to target the protease TNF-alpha convertase (TACE), which releases TNF-alpha from cells.

100 DEB TACE was followed by 3- and 7-day sacrifice, tumor harve

101 ecrosis in rabbit VX2 liver tumors after DEB TACE.

102 ntinuous sorafenib therapy and on-demand DEB TACE provided excellent local disease control and did no

103 Up to four rounds of DEB TACE therapy were allowed on demand within 6 months.

104 started 1 week before the first round of DEB TACE, which was performed in 6-week cycles.

105 ian weight, 2.8 kg) underwent successful DEB TACE.

106 of sorafenib therapy in combination with DEB TACE may have a survival benefit in patients with advanc

107 DEB-TACE response was based on modified Response Evaluation

108 DEB-TACE results in localization of drug to targeted tumors

109 achieved in 50.9% and 57.1% of cTACE and DEB-TACE patients, respectively; at least 50% necrosis was e

110 TACE with drug-eluting beads (DEB-TACE), a novel drug delivery system that produces a slow

111 ined with TACE using drug-eluting beads (DEB-TACE), which was given via the hepatic artery 2-5 weeks

112 g beads transarterial chemoembolization (DEB-TACE).

113 n-eluting microspheres (DEB) (hereafter, DEB-TACE) and subsequently underwent transplantation over a

114 urrence to assess independent effects of DEB-TACE response on recurrence.

115 s with HCC who underwent cTACE (n=76) or DEB-TACE (n=35) before OLT at a single center between Januar

116 Poor response to DEB-TACE (SD or DP) was present in 86% of cases and accounte

117 RPRETATION: The addition of sorafenib to DEB-TACE does not improve progression-free survival in Europ

118 Conclusion Response to DEB-TACE is correlated with tumor biology and patients at ri

119 ed in each group that were attributed to DEB-TACE.

120 gic response rate to cTACE compared with DEB-TACE in patients undergoing OLT has not been well descri

121 dol was performed for 159 procedures, DEBDOX TACE was performed for 47, and hqTACE was performed for

122 enhanced AP-2alpha expression and decreased TACE promoter luciferase activity in DCs.

123 ly, transfection of AP-2alpha cDNA decreased TACE promoter luciferase activity, TACE expression, and

124 g genetic mouse models to selectively delete TACE expression in oligodendrocyte progenitors cells (OP

125 Transarterial-chemo-embolization (TACE) is used for palliation of unresectable hepatocellu

126 ctivation of the TNF-alpha-converting enzyme TACE.

127 stimulates the TNF-alpha convertase enzyme (TACE/a disintegrin and metalloproteinase-17), leading to

128 roteases such as TNFalpha converting enzyme (TACE) (Ki = 4.45 +/- 0.48 muM).

129 an increase in TNF-alpha-converting enzyme (TACE) activity.

130 mor necrosis factor-alpha-converting enzyme (TACE) inhibitor, TAPI-2.

131 TNF-alpha converting enzyme (TACE) is a membrane-bound metalloprotease responsible fo

132 nase 17 (ADAM17)/TNFalpha Converting Enzyme (TACE) is associated with inflammatory disorders and canc

133 factor alpha (TNF-alpha)-converting enzyme (TACE) is at the center of inflammatory processes.

134 is generated by TNF-alpha converting enzyme (TACE) proteolytic release of the transmembrane TNF (tmTN

135 factor-alpha (TNF-alpha) converting enzyme (TACE) were also assessed.

136 mor necrosis factor-alpha converting enzyme (TACE) work together to regulate TH1 responses.

137 activity of the TNF-alpha-converting enzyme (TACE), arguing that MUC1 is required for CSE-induced and

138 mor necrosis factor-alpha converting enzyme (TACE), as a novel key modulator of oligodendrocyte (OL)

139 mor necrosis factor-alpha-converting enzyme (TACE), enhanced CXCL12-CXCR4-induced motility and rapid

140 its activator, TNF-alpha converting enzyme (TACE).

141 translocation of TNFalpha-converting enzyme (TACE/ADAM17).

142 mor necrosis factor alpha-converting enzyme (TACE; ADAM17, CD156b), the metalloproteinase shedding CD

143 ADAM 17 (TNF-alpha converting enzyme, TACE) is a potential target for cancer therapy, but the

144 rotease, ADAM17 (TNFalpha-converting enzyme, TACE).

145 emonstrate that iRHOM2 and myeloid-expressed TACE play a critical role in inflammatory arthritis and

146 ere measured at baseline and after the first TACE on contrast material-enhanced magnetic resonance im

147 We investigated the effect of the first TACE on parameters of liver function and tumor response

148 After the first TACE procedure, TACE was repeated twice in 4-week interv

149 ith multifocal, bilobar NELM after the first TACE procedure.

150 g the observational time (range, one to five TACE sessions).

151 nse (CR) rate was 82.9% for RS and 82.5% for TACE MWA (odds ratio, 1.0; 95% confidence interval [CI]:

152 recently described an essential function for TACE/ADAM17 in regulating oligodendrogenesis during post

153 ant trends in which survival was greater for TACE plus RT in patients with PVTT compared with those w

154 followed by 1-mm gelatin-sponge pellets, for TACE.

155 ACE inhibitor IC-3 or in cells isolated from TACE knock-out mice, mechanical strain did not release l

156 al prognosis who may not profit from further TACE sessions.

157 After making a treatment decision (e.g., TACE or surgery), physicians may discover that the alter

158 Our study identifies TACE as an essential player in OL regeneration that may

159 ole for chemotherapy-induced cytotoxicity in TACE effectiveness and supports the use of chemotherapeu

160 jection resulted in a significant decline in TACE activity, procollagen alpha1 (I), alpha smooth musc

161 EGFR overexpression in TACE deficient OLs in vivo restores OL development and p

162 Moreover, EGFR overexpression in TACE-deficient OPs in vivo overcomes the defects in OL d

163 EGFR overexpression in TACE-deficient OPs restores OL survival and development.

164 , we identified an AP-2alpha binding site in TACE promoter and demonstrated, using EMSAs and chromati

165 5:DR3 contributions to PRR outcomes included TACE-induced TNFSF15 cleavage to soluble TNFSF15; solubl

166 ased CD62L may be a consequence of increased TACE-mediated CD62L cleavage and potentially impairs imm

167 of AP-2alpha small interfering RNA increased TACE promoter luciferase activity, TACE expression, and

168 3 (Timp3), we hypothesized that AGEs induce TACE through nicotinamide adenine dinucleotide phosphate

169 h suppression of PPAR-gamma or ERK inhibited TACE activity and TNF-alpha secretion.

170 nerated a stable form of the auto-inhibitory TACE prodomain (TPD), which specifically inhibits in vit

171 predict patient survival early after initial TACE and enabled clear identification of nonresponders.

172 tivity Assay Kit, Fluorimetric, and InnoZyme TACE Activity Kit, respectively.

173 C5a and immune complexes, stimulated iRHOM2/TACE-dependent shedding of TNF-alpha in mouse and human

174 arthritis to the same extent as mice lacking TACE in myeloid cells or Tnfa-deficient mice.

175 current efficacy and safety data of lipiodol TACE in treatment of HCC.

176 figures of HCC patients undergoing lipiodol TACE appear to be in line with those reported in previou

177 tal of 10,108 patients treated with lipiodol TACE, were selected for the efficacy analysis.

178 of iRhom2 alter its interaction with mature TACE, thereby licensing its proteolytic activity.

179 Mechanistically, TACE regulates oligodendrogenesis by modulating the shed

180 ially, allow cleavage by the metalloprotease TACE (TNF-alpha-converting enzyme).

181 criptional activation of the metalloprotease TACE/ADAM17 (TNF-alpha-converting enzyme), a previously

182 In contrast, the matrix metalloproteinase/TACE (tumor necrosis factor-alpha-converting enzyme) inh

183 a catalytic antioxidant (CA) could modulate TACE-mediated LAG-3 shedding to impede diabetogenic T-ce

184 diagnosed with HCC and treated with multiple TACE cycles between January 1999 and December 2009 at th

185 Sixty-nine TACE procedures were performed during the observational

186 An absence of TACE was the only other independent risk factor of dropo

187 The activation of TACE is associated with the up-regulation of iRhom2 as w

188 gher, whereas the expression and activity of TACE were lower, in wild-type DCs (wtDCs) than in TNF kn

189 tifying a significant therapeutic benefit of TACE plus RT for unresectable HCC compared with TACE alo

190 ses of AP-2alpha expression and decreases of TACE expression and activity in wtDCs and TNFko DCs, ind

191 Genetic deletion of TACE in oligodendrocyte progenitor cells (OPs) induces p

192 nd 95% CIs were calculated for the effect of TACE plus RT vs TACE alone on survival, tumor response,

193 Side effects of TACE and sorafenib were comparable to those reported in

194 s to analyze retrospectively the efficacy of TACE and its impact on OS in patients with metastatic he

195 antially increase the safety and efficacy of TACE in comparison to conventional ethiodized oil-based

196 in mouse models, to enhance the efficacy of TACE.

197 The failure of TACE to exit the endoplasmic reticulum in the absence of

198 gest evaluating the technical feasibility of TACE in all metastatic patients.

199 Our study reveals an essential function of TACE in oligodendrogenesis, and demonstrates how this mo

200 Our study reveals an essential function of TACE in supporting OL regeneration and CNS remyelination

201 hieve selective gain- or loss-of-function of TACE or EGFR in OL lineage cells in vivo, we found that

202 apeutic target for selective inactivation of TACE in myeloid cells.

203 and cancer, a tissue-specific inhibition of TACE in immune cells appears mandatory.

204 Although specific inhibition of TACE is thought to be a viable strategy for inflammatory

205 the ER-to-Golgi transport and maturation of TACE.

206 The mechanisms of TACE and sTNF regulation in DCs remain elusive.

207 r that leverages the endogenous modulator of TACE.

208 The median number of TACE sessions per patient was 3 +/- 2.

209 ll as the interaction and phosphorylation of TACE and iRhom2, which are also NO/cGMP/protein kinase G

210 Rhbdf2 allows tissue-specific regulation of TACE by selectively preventing its maturation in immune

211 Because the main natural regulator of TACE activity is the tissue inhibitor of metalloproteina

212 ealed that TACE and a combination therapy of TACE and sorafenib were significant prognostic factors i

213 We studied the tolerability of TACE in a cohort of patients with NASH and alcoholic cir

214 furin-mediated maturation and trafficking of TACE to the cell surface, the site of TNF cleavage.

215 e classified as target progression (RS, one; TACE MWA, nine).

216 ional TACE with doxorubicin plus lipiodol or TACE with drug-eluting beads; 63 patients were treated w

217 Src or TACE inhibition was sufficient to attenuate DCA-induced

218 iver cancer with either conventional TACE or TACE with drug-eluting beads.

219 Here, we identify a p53/TACE pathway that is negatively regulated by FOS and sho

220 y regulated by FOS and show that the FOS/p53/TACE axis suppresses SCC by inducing differentiation.

221 We propose FOS/AP-1 inhibition or p53/TACE reactivating strategies as differentiation-inducing

222 ay p53-inactivating mutations, restoring p53/TACE activity in mouse and human skin SCCs induced tumor

223 , the least regretful strategy is to perform TACE on all patients.

224 m with elevated bilirubin predicted AHD post-TACE.

225 response of the index tumor on pre- and post-TACE magnetic resonance images was assessed retrospectiv

226 They were monitored for post-TACE complications: postembolization fever (PEF), nausea

227 There were no immediate post-TACE deaths.

228 ur size and female gender predicted PEF post-TACE.

229 After the first TACE procedure, TACE was repeated twice in 4-week intervals if indicated

230 a, which rely upon the cell surface protease TACE/ADAM-17.

231 phiregulin, p38 MAPK signalling and protease/TACE activity.

232 eolytic cleavage activation components (PS2, TACE) and restrained expression of the inhibitory compon

233 g TACE plus RT and a control group receiving TACE alone with data for at least 1-year survival or tum

234 ls that included a treatment group receiving TACE plus RT and a control group receiving TACE alone wi

235 se and total bilirubin in patients receiving TACE plus RT compared with those receiving TACE alone.

236 Patients receiving TACE plus RT showed significantly better 1-year survival

237 g TACE plus RT compared with those receiving TACE alone.

238 This study newly defines that sTNF regulates TACE in mouse DCs by engaging the AP-2alpha transcriptio

239 ception of the strategy and no pre-resection TACE are predictors of successful SLT strategy.

240 of liver transplantation compared to RFA +/- TACE was 1.5 months at 3 years (range -3.5 to 5.6) and 5

241 Conclusion SEB TACE resulted in minimal PSC, high ITSC, and sustained V

242 ze of VX2 tumors treated with 70-150-mum SEB TACE increased less (-2%) than that of tumors treated wi

243 d with major adverse events after the second TACE (P = 0.011).

244 An ART score of >/=2.5 prior the second TACE identifies patients with a dismal prognosis who may

245 and the presence of ascites prior the second TACE.

246 Mechanistically, uPAR sequestered TACE within lipid rafts to prevent Notch1 activation, th

247 -type and TACE knock-out cells using several TACE constructs demonstrated not only that integrins alp

248 ffect of redox modulation on LAG-3 shedding, TACE enzymatic function, and disease onset.

249 High glucose stimulated Src, TACE, epidermal growth factor receptor (EGFR), mitogen-a

250 ndicate a role for Src in a high glucose-Src-TACE-heparin-binding epidermal growth factor-EGFR-MAPK-s

251 ith HCC were treated with 232 superselective TACE procedures using C-arm cone-beam CT at one institut

252 ed, except in hematopoietic cells, supported TACE maturation and shedding of the EGFR ligand TGF-alph

253 cifically inhibits in vitro and cell-surface TACE, but not the related ADAM10, and effectively modula

254 RT was more therapeutically beneficial than TACE alone for treating HCC, and should be recommended f

255 sional progression were longer with TEA than TACE (TTP, 34.6 months [95% CI: 28.2, 41] vs 26.05 month

256 R in OL lineage cells in vivo, we found that TACE is critical for EGFR activation in OLs following de

257 Furthermore, we found that TACE-dependent activation of Notch1 in basal kerantinocy

258 ocyte progenitors cells (OPs), we found that TACE/ADAM17 is required for supporting OL regeneration f

259 yses and Cox regression models revealed that TACE and a combination therapy of TACE and sorafenib wer

260 These results show that TACE is a target of, and is downregulated by, sTNF-induc

261 mediated Rac activation is upstream from the TACE/EGFR/ERK pathway and regulates T678 phosphorylation

262 e complication rate was 8.9% and 4.9% in the TACE MWA and RS groups, respectively (P = .46).

263 ths (95% CI: 7.7 months, 19.1 months) in the TACE MWA group (P > .99).

264 Jun pathway, lead to the upregulation of the TACE (also known as ADAM17) inhibitor TIMP-3, and lead t

265 In contrast, in samples incubated with the TACE inhibitor IC-3 or in cells isolated from TACE knock

266 Patients underwent a median of three TACE cycles and received 13 infusions of bevacizumab ver

267 ha enhances epithelial wound healing through TACE, ERK, and GEF-H1.

268 itation assays, that AP-2alpha could bind to TACE promoter in a TNF-dependent manner.

269 only that integrins alpha6 and beta1 bind to TACE via the disintegrin domain but also that mechanical

270 Overall, iRhom2 binds to TACE throughout its lifecycle, implying that iRhom2 is a

271 servation was the lower complete response to TACE in the PHT group (12% vs. 36%; P = 0.001).

272 nal prognostic effect of adding sorafenib to TACE treatment in this patient cohort.

273 for the ongoing clinical program for the TPZ-TACE regimen in HCC treatment.

274 ndomised, placebo-controlled, phase 3 trial (TACE 2) in 20 hospitals in the UK for patients with unre

275 CC (July 2011 - December 2014), 84 underwent TACE.

276 h HCC hepatocellular carcinoma who underwent TACE transarterial chemoembolization before surgery.

277 9.6 years; age range, 23-72 years) underwent TACE with doxorubicin-eluting microspheres (DEB) (hereaf

278 Physician preferences on surgery versus TACE were elicited in terms of regret; threshold probabi

279 ib improves progression-free survival versus TACE with placebo.

280 calculated for the effect of TACE plus RT vs TACE alone on survival, tumor response, and adverse even

281 We aimed to determine whether TACE with sorafenib improves progression-free survival v

282 ted with sorafenib, 42 patients (19.5%) with TACE and 23 patients (10.7%) received treatment with TAC

283 e reveal that iRhom2 remains associated with TACE throughout the secretory pathway, and is stabilised

284 pies need to be assessed in combination with TACE to improve patient outcomes.

285 HIFU combined with TACE is a safe and promising method with a low rate of s

286 ice-daily) or matching placebo combined with TACE using drug-eluting beads (DEB-TACE), which was give

287 (OR, 2.73 [95% CI, 1.95-3.81]) compared with TACE alone.

288 E plus RT for unresectable HCC compared with TACE alone.

289 (ART score: Assessment for Retreatment with TACE) in the training cohort (n = 107, Vienna) by using

290 6.1, 12.3 months) for patients treated with TACE and 7.4 months (95% CI: 5.6, 9.2 months) for those

291 compared with those of patients treated with TACE MWA.

292 epatocellular carcinoma lesions treated with TACE transarterial chemoembolization .

293 mean age, 61.9 years +/- 10.7) treated with TACE with drug-eluting beads.

294 l of patients with HCC who were treated with TACE.

295 with unresectable HCC who were treated with TACE.

296 ) with multifocal, bilobar NELM treated with TACE.

297 23 patients (10.7%) received treatment with TACE and sorafenib in combination.

298 epatic HCC progression, local treatment with TACE may result in improved OS, although it is not recom

299 another form of therapy after treatment with TACE.

300 sis (PVTT), and time between treatments with TACE and RT were performed.